Ava Hosseini1, Jennifer L Baker1, Christopher A Tokin1, Zhengtao Qin2, David J Hall3, Dwayne G Stupak4, Tomoko Hayashi4, Anne M Wallace5, David R Vera6. 1. Department of Surgery, University of San Diego, California. 2. Department of Radiology, University of San Diego, California; In Vivo Cancer and Molecular Imaging Center, University of San Diego, California. 3. Department of Radiology, University of San Diego, California; In Vivo Cancer and Molecular Imaging Center, University of San Diego, California; Moores UCSD Cancer Center, University of San Diego, California. 4. Moores UCSD Cancer Center, University of San Diego, California; Department of Reproductive Medicine, University of San Diego, California. 5. Department of Surgery, University of San Diego, California; Moores UCSD Cancer Center, University of San Diego, California. 6. Department of Radiology, University of San Diego, California; In Vivo Cancer and Molecular Imaging Center, University of San Diego, California; Moores UCSD Cancer Center, University of San Diego, California. Electronic address: dvera@ucsd.edu.
Abstract
BACKGROUND: Dendritic cells (DC) are localized in close proximity to cancer cells in many well-known tumors, and thus maybe a useful target for tumor margin assessment. MATERIALS AND METHODS: [(99m)Tc]- cyanine 7 (Cy7)-tilmanocept was synthesized and in vitro binding assays to bone marrow-derived DC were performed. Fifteen mice, implanted with either 4T1 mouse mammary or K1735 mouse melanoma tumors, were administered 1.0 nmol of [(99m)Tc]-Cy7-tilmanocept via tail vein injection. After fluorescence imaging 1 or 2 h after injection, the tumor, muscle, and blood were assayed for radioactivity to calculate percent-injected dose. Digital images of the tumors after immunohistochemical staining for DC were analyzed to determine DC density. RESULTS: In vitro binding demonstrated subnanomolar affinity of [(99m)Tc]-Cy7-tilmanocept to DC (KA = 0.31 ± 0.11 nM). After administration of [(99m)Tc]-Cy7-tilmanocept, fluorescence imaging showed a 5.5-fold increase in tumor signal as compared with preinjection images and a 3.3-fold difference in fluorescence activity when comparing the tumor with the surgical bed after tumor excision. Immunohistochemical staining analysis demonstrated that DC density positively correlated with tumor percent of injected dose per gram (r = 0.672, P = 0.03), and higher DC density was observed at the periphery versus center of the tumor (186 ± 54 K versus 64 ± 16 K arbitrary units, P = 0.001). CONCLUSIONS: [(99m)Tc]-Cy7-tilmanocept exhibits in vitro and in vivo tumor-specific binding to DC and maybe useful as a tumor margin targeting agent.
BACKGROUND: Dendritic cells (DC) are localized in close proximity to cancer cells in many well-known tumors, and thus maybe a useful target for tumor margin assessment. MATERIALS AND METHODS:[(99m)Tc]- cyanine 7 (Cy7)-tilmanocept was synthesized and in vitro binding assays to bone marrow-derived DC were performed. Fifteen mice, implanted with either 4T1 mouse mammary or K1735 mousemelanoma tumors, were administered 1.0 nmol of [(99m)Tc]-Cy7-tilmanocept via tail vein injection. After fluorescence imaging 1 or 2 h after injection, the tumor, muscle, and blood were assayed for radioactivity to calculate percent-injected dose. Digital images of the tumors after immunohistochemical staining for DC were analyzed to determine DC density. RESULTS: In vitro binding demonstrated subnanomolar affinity of [(99m)Tc]-Cy7-tilmanocept to DC (KA = 0.31 ± 0.11 nM). After administration of [(99m)Tc]-Cy7-tilmanocept, fluorescence imaging showed a 5.5-fold increase in tumor signal as compared with preinjection images and a 3.3-fold difference in fluorescence activity when comparing the tumor with the surgical bed after tumor excision. Immunohistochemical staining analysis demonstrated that DC density positively correlated with tumor percent of injected dose per gram (r = 0.672, P = 0.03), and higher DC density was observed at the periphery versus center of the tumor (186 ± 54 K versus 64 ± 16 K arbitrary units, P = 0.001). CONCLUSIONS:[(99m)Tc]-Cy7-tilmanocept exhibits in vitro and in vivo tumor-specific binding to DC and maybe useful as a tumor margin targeting agent.
Authors: David R Vera; David J Hall; Carl K Hoh; Pascal Gallant; Laura M McIntosh; Robert F Mattrey Journal: Nucl Med Biol Date: 2005-10 Impact factor: 2.408
Authors: Lyse A Norian; Paulo C Rodriguez; Leigh A O'Mara; Jovanny Zabaleta; Augusto C Ochoa; Marina Cella; Paul M Allen Journal: Cancer Res Date: 2009-03-17 Impact factor: 12.701
Authors: Lee G Wilke; J Quincy Brown; Torre M Bydlon; Stephanie A Kennedy; Lisa M Richards; Marlee K Junker; Jennifer Gallagher; William T Barry; Joseph Geradts; Nimmi Ramanujam Journal: Am J Surg Date: 2009-10 Impact factor: 2.565
Authors: Rick G Pleijhuis; Maurits Graafland; Jakob de Vries; Joost Bart; Johannes S de Jong; Gooitzen M van Dam Journal: Ann Surg Oncol Date: 2009-07-17 Impact factor: 5.344
Authors: Hak J Lee; Christopher V Barback; Carl K Hoh; Zhengtao Qin; Kareem Kader; David J Hall; David R Vera; Christopher J Kane Journal: J Nucl Med Date: 2017-02-02 Impact factor: 10.057
Authors: Kristen M Anderson; Christopher V Barback; Zhengtao Qin; David J Hall; Carl K Hoh; David R Vera; Michael T McHale Journal: PLoS One Date: 2018-07-02 Impact factor: 3.240